Wanbury FY26 PAT surges 117% to Rs. 66.1 crore

Supriya Lifescience posts 50% revenue growth in Q4 FY26; PAT rises to Rs 74 crore

On a full-year basis, revenue from operations for FY26 grew 18.9 percent year-on-year to Rs 827.87 crore compared to Rs 696.48 crore in FY25

Nihon Kohden launches Life Scope E7 patient monitoring platform in India

CDSCO-cleared BSM-5700 series targets ICU, NICU, ER, OR and digital health integration under ABDM

Irish medtech firm InVera Medical wins EU nod for breakthrough vein treatment device

Supriya Lifescience delivers robust Q3 FY26 performance with 11% YoY revenue growth

The Profit After Tax (PAT) for Q3 FY26 was Rs 49.68 crore, compared to Rs 46.78 crore in Q3 FY25

Wanbury reports explosive Q3 profit surge, signals strong growth ahead

Call it one of the most striking turnarounds in the Indian pharma sector this fiscal year

Wanbury achieves first sales invoicing and commercial shipment milestone

This achievement validates global demand and catapults Wanbury into high-growth acceleration

Wanbury unveils API facility in Tanuku, targets Rs. 100 crore revenue

The Tanuku facility will focus on the production of key therapeutic APIs, including Anti-Tussive, Anti-Coagulant (Blood Thinner), Anaesthetic, and Antidepressant molecules

Zydus receives final approval from USFDA for Lidocaine and Prilocaine Cream USP

Lidocaine and Prilocaine cream had annual sales of US $22.05 million in the United States (IQVIA MAT October 2024)

Supriya Lifescience reports 19% revenue increase in Q2 FY25

The company reported a net profit of Rs 46.15 crore in Q2 FY25 as compared to Rs 23.88 crore in Q2 FY24